Stay updated with breaking news from Misleading Risk. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
The wait is finally over. On June 7, 2023, after remaining silent for over an entire year, the US Food and Drug Administration ("FDA") Office of Prescription Drug Promotion ("OPDP") issued its first untitled...
The wait is finally over. On June 7, 2023, after remaining silent for over an entire year, the US Food and Drug Administration (“FDA”) Office of Prescription Drug Promotion (“OPDP”)...
US FDA OPDP issued first untitled letter of 2023 to Xeris Pharmaceuticals concerning promotional material for Recorlev tablets, citing misleading claims on company webpages.